Reply: Assessment of therapeutic response in patients with metastatic skeletal disease: suggested modifications for the MDA response classification criteria

Por Hamaoka, T, Costelloe, C M, Madewell, J E, Liu, P, Hortobagyi, G N, Ueno, N T
Publicado em 2010

Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer

Por Hamaoka, T, Costelloe, C M, Madewell, J E, Liu, P, Berry, D A, Islam, R, Theriault, R L, Hortobagyi, G N, Ueno, N T
Publicado em 2010

Osseous Pseudoprogression in Vertebral Bodies Treated with Stereotactic Radiosurgery: A Secondary Analysis of Prospective Phase I/II Clinical Trials

Por Amini, B., Beaman, C.B., Madewell, J.E., Allen, P.K., Rhines, L.D., Tatsui, C.E., Tannir, N.M., Li, J., Brown, P.D., Ghia, A.J.
Publicado no AJNR Am J Neuroradiol (2016)

Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard

Por Livingston, J. A., Bugano, D., Barbo, A., Lin, H., Madewell, J. E., Wang, W. L., Lazar, A. J., Tseng, W. W., Roland, C. L., Feig, B. W., Pollock, R., Conley, A. P., Benjamin, R. S., Patel, S., Somaiah, N.
Publicado no Sci Rep (2017)

Assessing vascular effects of adding bevacizumab to neoadjuvant chemotherapy in osteosarcoma using DCE-MRI

Por Guo, J, Glass, J O, McCarville, M B, Shulkin, B L, Daryani, V M, Stewart, C F, Wu, J, Mao, S, Dwek, J R, Fayad, L M, Madewell, J E, Navid, F, Daw, N C, Reddick, W E
Publicado no Br J Cancer (2015)